Daiichi Sankyo, Forest Labs Pay $300 Million to Settle Benicar Claims

TRENTON, N.J. — Daiichi Sankyo Inc. and Forest Laboratories Inc. have agreed to pay $300 million to settle approximately 2,300 federal and state court actions accusing them of failing to warn that their olmesartan-containing drugs Benicar, Benicar HCT, Azor and Tribenzor can cause severe gastrointestinal problems.

According to an Aug. 1 statement by Daiichi, The settlement requires, among other thresholds, that at least 95 percent of all eligible litigants and claimants decide to opt-in to the settlement under certain conditions. Claimants eligible to opt-in to the settlement program, under certain conditions, include those with claims already filed in court (currently …